Alexander W. Schüttelkopf

Alexander W. Schüttelkopf

Auto-generated profile, based on publicly available information

Alexander W. Schüttelkopf

Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JBJoanna L. Birch
Joanna L. Birch
KSKaren Strathdee
Karen Strathdee
LGLesley Gilmour
Lesley Gilmour
AVAntoine Vallatos
Antoine Vallatos
LMLaura McDonald
Laura McDonald
ACAnthony Chalmers
Anthony Chalmers
Glioblastoma (GBM) is an aggressive and incurable primary brain tumor that causes severe neurologic, cognitive, and psychologic symptoms. Symptoms are caused and exacerbated by the infiltrative properties of GBM cells, which enable them to pervade the healthy brain and disrupt normal function. Recent research has indicated that although radiotherapy (RT) remains the most effective component of multimodality therapy for patients with GBM, it can provoke a more infiltrative phenotype in GBM cells that survive treatment. Here, we demonstrate an essential role of the actin-myosin regulatory kinase myotonic dystrophy kinase-related CDC42-binding kinase (MRCK) in mediating the proinvasive effects of radiation. MRCK-mediated invasion occurred via downstream signaling to effector molecules MYPT1 and MLC2. MRCK was activated by clinically relevant doses per fraction of radiation, and this activation was concomitant with an increase in GBM cell motility and invasion. Furthermore, ablation of MRCK activity either by RNAi or by inhibition with the novel small-molecule inhibitor BDP-9066 prevented radiation-driven increases in motility both in vitro and in a clinically relevant orthotopic xenograft model of GBM. Crucially, treatment with BDP-9066 in combination with RT significantly increased survival in this model and markedly reduced infiltration of the contralateral cerebral hemisphere. Significance: An effective new strategy for the treatment of glioblastoma uses a novel, anti-invasive chemotherapeutic to prevent infiltration of the normal brain by glioblastoma cells.Cancer Res; 78(22); 6509–22. ©2018 AACR.

31 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CPCharles W. Parry
Charles W. Parry
FPFrancesca Pellicano
Francesca Pellicano
ASAlexander W. Schüttelkopf
Alexander W. Schüttelkopf
KBKim S. Beyer
Kim S. Beyer
JBJustin Bower
Justin Bower
JTJohn Taylor
John Taylor

31 March 2023
Verified
Other
Open access
JBJoanna L. Birch
Joanna L. Birch
KSKaren Strathdee
Karen Strathdee
LGLesley Gilmour
Lesley Gilmour
AVAntoine Vallatos
Antoine Vallatos
LMLaura McDonald
Laura McDonald
ACAnthony Chalmers
Anthony Chalmers
Increased GBM cell invasion in vivo is confirmed by a human specific antibody against HLA and measurement of tumour volume by multi-slice T2 MR imaging

31 March 2023
Verified
Other
Open access
JBJoanna L. Birch
Joanna L. Birch
KSKaren Strathdee
Karen Strathdee
LGLesley Gilmour
Lesley Gilmour
AVAntoine Vallatos
Antoine Vallatos
LMLaura McDonald
Laura McDonald
ACAnthony Chalmers
Anthony Chalmers
Subconfluent migration assay in the presence of DMSO

31 March 2023
Verified
Other
Open access
JBJoanna L. Birch
Joanna L. Birch
KSKaren Strathdee
Karen Strathdee
LGLesley Gilmour
Lesley Gilmour
AVAntoine Vallatos
Antoine Vallatos
LMLaura McDonald
Laura McDonald
ACAnthony Chalmers
Anthony Chalmers
Subconfluent migration assays in the presence of 1000nM BDP-9066

31 March 2023
Verified
Other
Open access
JBJoanna L. Birch
Joanna L. Birch
KSKaren Strathdee
Karen Strathdee
LGLesley Gilmour
Lesley Gilmour
AVAntoine Vallatos
Antoine Vallatos
LMLaura McDonald
Laura McDonald
ACAnthony Chalmers
Anthony Chalmers
Untreated GFP E2 cells in an ex vivo brain slice motility assay